Phenethyldihydrobenzodioxolone Microtubule Inhibitors for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic agents for treating solid tumors have not significantly evolved in the last twenty years, with most relying on nitrogen mustards, antifolates, platinums, nucleoside analogues, taxanes, and anthracyclines, and targeted therapies have not fulfilled expectations, necessitating new microtubule inhibitors for effective cancer treatment.
Innovation Solution
Development of phenethyldihydrobenzodioxolone compounds with a 7,7a-dihydro-7a-phenethylbenzo[d][1,3]dioxol-5(6H)-one scaffold that inhibit tubulin polymerization, offering new chemotherapeutic options as monotherapies or in combination with targeted therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic agents (nitrogen mustards, antifolates, platinums, nucleoside analogues, taxanes, and anthracyclines) are used to treat solid tumors, then current treatment protocols are maintained, but therapeutic efficacy does not significantly improve
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified molecular structures (phenethyldihydrobenzodioxolone scaffold) that interact with microtubules through different mechanisms than existing chemotherapies. This structural parameter change enables novel therapeutic effects while maintaining microtubule inhibition as the core mechanism of action.
Solution Approach 2:
The invention segments the broad category of chemotherapeutic agents into distinct mechanistic classes, specifically isolating microtubule inhibitors as a separate therapeutic avenue. By focusing on this specific segment and developing new compounds within this class (bifidenone and analogues), the patent creates specialized treatment options that address the limitations of traditional multi-class chemotherapy approaches.
2Adaptability or versatility
If targeted therapies are developed based on genomics efforts, then new treatment approaches are introduced, but they must still be combined with traditional non-selective chemotherapies
Solution Approach 1:
The patent applies universality by designing phenethyldihydrobenzodioxolone compounds that serve multiple therapeutic functions. These microtubule inhibitors can be used as monotherapies for various solid tumors and simultaneously serve as effective combination partners with targeted therapies, reducing the need for complex multi-agent regimens while maintaining versatility across different cancer types.
3Reliability
If new microtubule inhibitors are developed, then antiproliferative activity is enhanced, but compound structure complexity increases
Solution Approach 1:
The patent applies local quality by making specific, targeted modifications to the phenethyldihydrobenzodioxolone molecular scaffold at particular positions (R1-R5 substituents) rather than redesigning the entire molecule. This localized approach to structural optimization enhances antiproliferative activity through specific substituent patterns while maintaining the core scaffold's efficiency and avoiding unnecessary overall structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The phenethyldihydrobenzodioxolone compounds demonstrate potent antiproliferative activity, interacting with microtubules and inhibiting tumor growth, providing a promising approach for treating various cancers and other proliferative diseases, including carcinoma and hematopoietic tumors.
Implementation Method 1
bifidenone has a phenethyldihydrobenzodioxolone scaffold and inhibits tubulin polymerization
Implementation Method 2
The phenethyldihydrobenzodioxolone compounds demonstrate potent antiproliferative activity, interacting with microtubules and inhibiting tumor growth
Data Source
AI summary
The present invention generally relates to phenethyldihydrobenzodioxolone compounds and compositions useful for reducing or inhibiting tumor growth. It also relates to methods of use and the preparation of phenethyldihydrobenzodioxolone compounds.